[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100350071":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":36,"responsibleParty":222,"collaborators":225,"id":228,"slug":229,"hasResults":230,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":30,"eligibilityCriteria":234,"healthyVolunteers":230,"sex":235,"minAge":236,"maxAge":237,"enrollmentInfo":238,"targetDuration":30,"studyType":241,"phases":242,"briefSummary":245,"conditions":246,"keywords":249,"overallStatus":39,"whyStopped":30,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":261},{"fullName":5,"class":6},"University Hospital Heidelberg","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Nivolumab and Entinostat","EXPERIMENTAL","Combination Study of Nivolumab and Entinostat",[13],"Drug: Nivolumab and Entinostat",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.",[9],[20],"Opdivo",[22],{"name":23,"affiliation":5,"role":24},"Olaf Witt","PRINCIPAL_INVESTIGATOR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Venukah Schäfer","CONTACT","+496221 56 7267",null,"venukah.schaefer@kitz-heidelberg.de",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},"Melanie Heiß","+496221 56 7255","melanie.heiss@kitz-heidelberg.de",[37,54,66,79,92,106,120,134,145,156,167,182,195,208],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Sydney Children's Hospital","RECRUITING","Randwick","New South Wales","2031","Australia","AU",{"type":46,"coordinates":47},"Point",[48,49],151.24895,-33.91439,{"lat":49,"lon":48},[52],{"name":53,"role":24,"phone":30,"phoneExt":30,"email":30},"David Ziegler",{"facility":55,"status":39,"city":56,"state":41,"zip":57,"country":43,"countryCode":44,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Children's Hospital at Westmead","Westmead","2145",{"type":46,"coordinates":59},[60,61],150.98768,-33.80383,{"lat":61,"lon":60},[64],{"name":65,"role":24,"phone":30,"phoneExt":30,"email":30},"Dinisha Govender",{"facility":67,"status":39,"city":68,"state":69,"zip":70,"country":43,"countryCode":44,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Royal Children's Hospital","Parkville","Victoria","3052",{"type":46,"coordinates":72},[73,74],144.95,-37.78333,{"lat":74,"lon":73},[77],{"name":78,"role":24,"phone":30,"phoneExt":30,"email":30},"Dong Anh Khuong Quang",{"facility":80,"status":39,"city":81,"state":82,"zip":83,"country":43,"countryCode":44,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Perth Children's Hospital","Nedlands","Western Australia","6009",{"type":46,"coordinates":85},[86,87],115.8073,-31.98184,{"lat":87,"lon":86},[90],{"name":91,"role":24,"phone":30,"phoneExt":30,"email":30},"Nick Gottardo",{"facility":93,"status":39,"city":94,"state":30,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"St. Anna Children's Hospital","Vienna","1090","Austria","AT",{"type":46,"coordinates":99},[100,101],16.37208,48.20849,{"lat":101,"lon":100},[104],{"name":105,"role":24,"phone":30,"phoneExt":30,"email":30},"Caroline Hutter",{"facility":107,"status":39,"city":108,"state":30,"zip":109,"country":110,"countryCode":111,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Institut Curie","Paris","75005","France","FR",{"type":46,"coordinates":113},[114,115],2.3488,48.85341,{"lat":115,"lon":114},[118],{"name":119,"role":24,"phone":30,"phoneExt":30,"email":30},"Gudrun Schleiermacher",{"facility":121,"status":39,"city":122,"state":30,"zip":123,"country":124,"countryCode":125,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"Augsburg University Hospital","Augsburg","86156","Germany","DE",{"type":46,"coordinates":127},[128,129],10.89851,48.37154,{"lat":129,"lon":128},[132],{"name":133,"role":24,"phone":30,"phoneExt":30,"email":30},"Michael Frühwald, Prof.Dr.Dr.",{"facility":135,"status":39,"city":136,"state":30,"zip":30,"country":124,"countryCode":125,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Charité University Medicine Berlin","Berlin",{"type":46,"coordinates":138},[139,140],13.41053,52.52437,{"lat":140,"lon":139},[143],{"name":144,"role":24,"phone":30,"phoneExt":30,"email":30},"Anne Thorwarth, Dr. med.",{"facility":146,"status":39,"city":147,"state":30,"zip":30,"country":124,"countryCode":125,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Essen University Hospital","Essen",{"type":46,"coordinates":149},[150,151],7.01228,51.45657,{"lat":151,"lon":150},[154],{"name":155,"role":24,"phone":30,"phoneExt":30,"email":30},"Uta Dirksen, Prof.Dr.med.",{"facility":157,"status":39,"city":158,"state":30,"zip":30,"country":124,"countryCode":125,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Hannover Medical School","Hanover",{"type":46,"coordinates":160},[161,162],9.73322,52.37052,{"lat":162,"lon":161},[165],{"name":166,"role":24,"phone":30,"phoneExt":30,"email":30},"Andreas Beilken, Dr. med.",{"facility":168,"status":39,"city":169,"state":30,"zip":170,"country":124,"countryCode":125,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Hopp Children's Cancer Center Heidelberg (KiTZ)","Heidelberg","69120",{"type":46,"coordinates":172},[173,174],8.69079,49.40768,{"lat":174,"lon":173},[177,180],{"name":178,"role":28,"phone":30,"phoneExt":30,"email":179},"INFORM2 Team","inform2@kitz-heidelberg.de",{"name":181,"role":24,"phone":30,"phoneExt":30,"email":30},"Olaf Witt, Prof.Dr.med.",{"facility":183,"status":39,"city":184,"state":30,"zip":30,"country":185,"countryCode":186,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Prinses Máxima Centrum","Utrecht","Netherlands","NL",{"type":46,"coordinates":188},[189,190],5.12222,52.09083,{"lat":190,"lon":189},[193],{"name":194,"role":24,"phone":30,"phoneExt":30,"email":30},"Jasper van der Lugt",{"facility":196,"status":39,"city":197,"state":30,"zip":30,"country":198,"countryCode":199,"cosmosGeoPoint":200,"geoPoint":204,"contacts":205},"Karolinska Institute","Stockholm","Sweden","SE",{"type":46,"coordinates":201},[202,203],18.06871,59.32938,{"lat":203,"lon":202},[206],{"name":207,"role":24,"phone":30,"phoneExt":30,"email":30},"Anna Nilsson",{"facility":209,"status":39,"city":210,"state":30,"zip":211,"country":212,"countryCode":213,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"Children's Hospital Zurich","Zurich","8032","Switzerland","CH",{"type":46,"coordinates":215},[216,217],8.55,47.36667,{"lat":217,"lon":216},[220],{"name":221,"role":24,"phone":30,"phoneExt":30,"email":30},"Nicolas Gerber",{"type":24,"investigatorFullName":223,"investigatorTitle":224,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Olaf Witt, MD","Prof. Dr. Olaf Witt",[226],{"name":227,"class":6},"German Cancer Research Center","100350071","phase-1-inform2-study-uses-nivolumab-and-entinostat-in-children-and-adolescents-with-high-risk-refractory-malignancies-100350071",false,"NCT03838042","INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies","INFORM2 Exploratory Multinational Phase I\u002FII Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt)","Inclusion Criteria:\n\n* Children and adolescents with refractory\u002Frelapsed\u002Fprogressive high-risk\n\n  * CNS tumors: medulloblastoma, ependymoma, ATRT, ETMR, pediatric high grade glioma (including DIPG) or other pediatric embryonal CNS tumors OR\n  * solid tumors: neuroblastoma, nephroblastoma, rhabdoid tumor, embryonal or alveolar rhabdomyosarcoma, other embryonal small round blue cell tumors including pediatric type (bone) sarcoma or other pediatric type solid tumors OR\n  * Children and adolescents with newly diagnosed high grade glioma (HGG) in the context of a constitutional mismatch repair deficiency syndrome after maximum safe surgical resection with no established standard of care treatment option with curative intention available. In addition in France: ineligible to radiotherapy\n* No standard of care treatment available\n* Age at registration ≥ 2 to ≤ 21 years\n* Molecular analysis for biomarker identification (SNV load, MYC\u002FN amplification, high TILs or TLS positive) in laboratories complying with DIN EN ISO\u002FIEC 17025 or similar via INFORM molecular diagnostic platform or equivalently valid molecular pipeline\n* Biomarker determined using whole exome sequencing (SNV load), whole genome- or whole exome sequencing (MYC\u002FN amplification), IHC (high TILs or TLS positive)\n* In case molecular analysis was not performed via INFORM Registry molecular pipeline: transfer of molecular data (whole exome sequencing)\n* Time between biopsy\u002Fpuncture\u002Fresection of the current refractory\u002Frelapsed\u002Fprogressive tumor and registration ≤ 24 weeks. In patients receiving therapy not impacting biomarker stratification, time between biopsy\u002Fpuncture\u002Fresection of the current refractory\u002Frelapsed\u002Fprogressive tumor and registration of ≤ 36 weeks is allowed\n* Disease that is measurable as defined by RANO criteria or RECIST v1.1 (as appropriate).\n* Life expectancy \\> 3 months, sufficient general condition score (Lansky ≥ 70 or Karnofsky ≥ 70). Transient states like infections requiring antibiotic treatments can be accepted, and also stable disabilities resulting from disease\u002Fsurgery (hemiparesis, amputations etc.) can be accepted and will not be considered for Lansky\u002FKarnofsky assessments.\n* Laboratory requirements:\n\n  * Hematology:\n\n    * absolute granulocytes ≥ 1.0 × 109\u002Fl (unsupported)\n    * platelets ≥ 100 × 109\u002Fl \\& stable\n    * hemoglobin ≥ 8 g\u002Fdl or ≥ 4.96 mmol\u002FL\n  * Biochemistry:\n\n    * Total bilirubin ≤ 1.5 x upper limit of normal (ULN)\n    * AST(SGOT) ≤ 3.0 x ULN\n    * ALT(SGPT) ≤ 3.0 x ULN\n    * serum creatinine ≤ 1.5 x ULN for age\n* ECG: normal QTc interval according to Bazett formula \\\u003C 440ms\n* Patient is able to swallow oral study medication\n* Ability of patient and\u002For legal representative(s) to understand the character and individual consequences of clinical trial\n* Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to initiation of treatment. Sexually active women of childbearing potential must agree to use acceptable and appropriate contraception during the study and for at least 6 months after the last study treatment administration. Sexually active male patients must agree to use a condom during the study and for at least 3 months after the last study treatment administration.\n* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial\n* Before patient screening and registration, written informed consent, also concerning data and blood transfer, must be given according to ICH\u002FGCP, and national\u002Flocal regulations.\n* No prior therapy with the combination of immune checkpoint inhibitors and HDACi\n* Phase I: molecular analysis performed and biomarker status known (mutational load, high TILs or TLS positive AND MYC(N) amplification status).\n* Phase II: molecular analysis performed, biomarker status known (mutational load, high TILs or TLS positive AND MYC(N) amplification status) and stratification according to the following criteria:\n\n  * Group A: high mutational load (defined as \\> 100 somatic SNVs\u002Fexome) based on whole exome sequencing OR\n  * Group C: Focal MYC(N) amplification based on whole genome sequencing or whole exome sequencing ot ATRT-MYC subgroup OR\n  * Group E: high TILs or TLS positive (defined as cells per mm² \\> 600 or presence of tertiary lymphoid structure) based on IHC analysis.\n\nExclusion Criteria:\n\n* Patients with CNS tumors or metastases who are neurologically unstable despite adequate treatment (e.g. convulsions).\n* Patients with low-grade gliomas or tumors of unknown malignant potential are not eligible\n* Evidence of \\> Grade 1 recent CNS hemorrhage on the baseline MRI scan.\n* Participants with bulky CNS tumor on imaging are ineligible; bulky tumor is defined as:\n\n  * Tumor with any evidence of uncal herniation or severe midline shift\n  * Tumor with diameter of \\> 6 cm in one dimension on contrast-enhanced MRI\n  * Tumor that in the opinion of the investigator, shows significant mass effect\n* Previous allogeneic bone marrow, stem cell or organ transplantation\n* Diagnosis of immunodeficiency\n* Diagnosis of prior or active autoimmune disease\n* Evidence of interstitial lung disease\n* Any contraindication to oral agents or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the investigator, would preclude adequate absorption.\n* Known history of human immunodeficiency virus (HIV) (HIV 1\u002F2 antibodies). Known active hepatitis B (e.g., hepatitis B surface antigen-reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid \\[qualitative\\]). Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[HBc Ab\\] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior to study treatment. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Clinically significant, uncontrolled heart disease\n* Major surgery within 21 days of the first dose. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48 hour interval must be maintained before the first dose of the investigational drug is administered.\n* Any anticancer therapy (e.g., chemotherapy, HDACi (including valproic acid), DNA methyltransferase inhibitors, other immunotherapy, targeted therapy, biological response modifiers, endocrine anticancer therapy or radiotherapy) within 2 weeks or at least 5 half- lives (whichever is longer) of study drug administration.\n* Radiologically confirmed radiotherapy induced pseudoprogression in CNS tumors\n* Traditional herbal medicines; these therapies are not fully studied and their use may result in unanticipated drug-drug interactions that may cause or confound the assessment of toxicity. As part of the enrollment\u002Finformed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the- counter medicine or herbal product. For information on CYP substrates and P-gp inhibitors or inducers see section 5.8.\n* History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form (including benzamide) of the investigational medicinal product\n* Participation in other ongoing clinical trials.\n* Pregnant or lactating females.\n* Presence of underlying medical condition (e.g. gastrointestinal disorders or electrolyte disturbances) that in the opinion of the Investigator or Sponsor could adversely affect the ability of the subject to comply with or tolerate study procedures and\u002For study therapy, or confound the ability to interpret the tolerability of combined administration of entinostat and nivolumab in treated subjects\n* Patients receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. The use of physiologic doses of corticosteroids (up to 5 mg\u002Fm2\u002Fday prednisone equivalent) may be approved after consultation with the Sponsor. No patient will be allowed to enroll in this trial more than once.","ALL","2 Years","21 Years",{"count":239,"type":240},91,"ESTIMATED","INTERVENTIONAL",[243,244],"PHASE1","PHASE2","The aim of this trial is to determine preliminary activity of the combination treatment with nivolumab and entinostat in children and adolescents with high risk refractory\u002Frelapsed\u002Fprogressive tumors harboring a high mutational load, focal MYC(N) amplification or ATRT-MYC subgroup as well as tumors with high tumor infiltrating lymphocytes (TILs) or a tertiary lymphoid structure (TLS).",[247,248],"CNS Tumor","Solid Tumor",[250,251],"high-risk solid tumors","high-risk CNS tumors","2024-02-05",{"date":254,"type":255},"2024-02-07","ACTUAL",{"date":257,"type":255},"2020-05-26",{"date":259,"type":240},"2027-06-30",{"name":5,"class":6},14]